Sharing success to unlock the “triple win” of joint workingThe fortunes of the NHS and the UK’s life sciences industry are intertwined, with each sector’s success or Share XSharing success to unlock the “triple win” of joint workinghttps://pharmaphorum.com/r-d/views-analysis-r-d/sharing-success-to-unlock-the-triple-win-of-joint-working/
Bringing innovative trials to the UKWe spoke with the National Institute for Health Research’s (NIHR) senior business development manager, Anjna Rising, to learn Share XBringing innovative trials to the UKhttps://pharmaphorum.com/r-d/views-analysis-r-d/bringing-innovative-trials-to-the-uk/
Addressing the medical cannabis knowledge gapThe legalisation of medical cannabis in November 2018 was hailed as a landmark victory for the British medical Share XAddressing the medical cannabis knowledge gaphttps://pharmaphorum.com/views-analysis-market-access/addressing-the-medical-cannabis-knowledge-gap/
Weekly roundup: Are actions stronger than words for Johnson and the NHS?It’s usually important for a new Conservative Party prime minister to make pledges within their first month in Share XWeekly roundup: Are actions stronger than words for Johnson and the NHS?https://pharmaphorum.com/views-and-analysis/weekly-roundup-are-actions-stronger-than-words-for-johnson-and-the-nhs/
Revealing the true value of new cancer drugs to payersMarc Botteman and Ben van Hout from Pharmerit International discuss how to navigate the value challenges of new Share XRevealing the true value of new cancer drugs to payershttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/pharmerit-cancer-drug-value-payers/
Tackling the remaining challenges of multiple sclerosisWith Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond Share XTackling the remaining challenges of multiple sclerosishttps://pharmaphorum.com/r-d/views-analysis-r-d/tackling-the-remaining-challenges-of-multiple-sclerosis/
Time to build evidence for patient involvement in researchPatient and public involvement (PPI) may be increasingly seen as the “right thing to do”, but without systematic Share XTime to build evidence for patient involvement in researchhttps://pharmaphorum.com/views-analysis-patients/time-to-build-evidence-for-patient-involvement-in-research/
AstraZeneca and lung cancer: the pharmaphorum podcastThis episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, global franchise head, Tagrisso TDR Share XAstraZeneca and lung cancer: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/astrazeneca-and-lung-cancer
Embracing New Science for new growthThere is a quiet force in the biopharmaceutical industry that could have notable implications. The industry is clearly Share XEmbracing New Science for new growthhttps://pharmaphorum.com/r-d/views-analysis-r-d/new-science-for-new-growth/
